Monoclonal antibody antitoxins for inhalational anthrax — the toxin-neutralizing biologics (raxibacumab and obiltoxaximab) representing the first major therapeutic innovation beyond antibiotics in anthrax treatment, now standard inclusions in the U.S. Strategic National Stockpile — create the most strategically significant market segment, with the Anthrax Treatment Market reflecting...